Journal of the American Heart Association

MARCH 8, 2024

In our study population of 1000 thrombectomy‐eligible patients (513 women; median age, 77 years [interquartile range, 67–84]), IVT emerged as a predictor of favorable functional outcome (modified Rankin Scale score, 0–2) independent of modified mTICI score (adjusted odds ratio, 0.49 [95% CI, 0.32–0.75];P=0.001). 0.75];P=0.001).

Thrombolysis 45

Thrombolysis Outcomes Stroke Strokes 45

Stroke Journal

FEBRUARY 1, 2024

We performed sensitivity analysis using propensity score matching.Results:In our study population of 1000 thrombectomy-eligible patients (513 females, median age 77 [67-84, interquartile range]) IVT emerged as predictor of favorable functional outcome (mRS 0-2) independent of mTICI (adjusted OR 0.49; 95% CI [0.32;0.75]; p=0.001).

Thrombolysis 40

Thrombolysis Outcomes Stroke Strokes 40

Stroke Journal

FEBRUARY 1, 2024

The role of adjunctive intravenous thrombolysis, such as intravenous tissue plasminogen activator (IVtPA), with MT remains unclear, especially for medium vessel occlusion (MeVO). In univariable regression, all outcomes were comparable between the two groups, except for higher mRS 0-2 rates in the MT+IVtPA group.

Thrombolysis 40

Thrombolysis Academic Hemorrhage Outcomes 40

Stroke Journal

FEBRUARY 1, 2024

However, clinical outcomes remain similar. This study compares post-thrombectomy outcomes in both groups, matched by initial NIHSS scores.Method:From October 2017 to March 2023, we studied LVO cases undergoing thrombectomy for acute ischemic stroke. Devastating outcomes were higher in ICAD group (15% vs 39%,P=0.027).

Outcomes 40

Outcomes Embolism Atrial Fibrillation Thrombolysis 40

Stroke Journal

FEBRUARY 1, 2024

Pre-transfer variables independently associated with clinical improvement were intravenous thrombolysis use, more distal occlusions, and lower serum glucose; variables associated with deterioration included more proximal occlusions and higher serum glucose.

Hospital 40

Hospital Outcomes Thrombolysis Document 40

Stroke Journal

FEBRUARY 1, 2024

Introduction:Tenecteplase improves reperfusion and functional outcomes in stroke patients with large vessel occlusion. Primary outcome was mRS at 90 days. Secondary outcomes were NIHSS at 24 hours and at discharge. Secondary outcomes were NIHSS at 24 hours and at discharge. Median NIHSS at presentation (18.0 versus 16.0,

Stroke 40

Stroke Strokes Thrombolysis Hemorrhage 40

Stroke Journal

FEBRUARY 1, 2024

of these patients received IV thrombolysis and 32.4% received IV thrombolysis and 43.9% Further studies are needed to determine why young adults with LVO with LAA have worse outcomes. Introduction:The incidence of Large Vessel Occlusion-Acute Ischemic Stroke (LVO-AIS) continues to increase in young adults. went home, 12.9%

Stroke 40

Stroke Strokes Atherosclerosis Thrombolysis 40